Matteo S. Carlino, MD, PhD, FRACP

Matteo S. Carlino, MD, PhD, FRACP, discussed immune-related adverse event rates with V940 added to pembrolizumab.

Matteo S. Carlino, MD, PhD, FRACP, reviewed efficacy data for V940 plus pembrolizumab in resected melanoma.

Matteo S. Carlino, MD, PhD, FRACP, explains how the individualized neoantigen therapy V940 is designed and delivered in melanoma.